Revision as of 19:32, 1 April 2021

Page editor		Section editor
	Ivy Abraham, MD University of Chicago Ingalls Memorial Hospital Harvey, IL		Neeta K. Venepalli, MD, MBA University of Illinois at Chicago Chicago, IL

0 regimens on this page 0 variants on this page

Note: there is some overlap, especially in the earlier literature, between treatment regimens for periampullary adenocarcinoma and those for pancreatic adenocarcinoma, cholangiocarcinoma, and gallbladder cancer; please see those pages for additional regimens.

Guidelines

ESMO

2016: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed

NCCN

NCCN Guidelines - Hepatobiliary Cancers

Adjuvant therapy

Observation

back to top

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Takada et al. 2002	1986-1992	Phase III (C)	5-FU & Mitomycin	Did not meet primary endpoint of OS
Neoptolemos et al. 2012 (ESPAC-3)	2000-2008	Phase III (C)	1. FULV 2. Gemcitabine	Did not meet primary endpoint of OS

No adjuvant therapy.

Preceding treatment

Surgery

References

Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002 Oct 15;95(8):1685-95. link to original article PubMed
ESPAC-3: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. link to original article PubMed NCT00058201

@@ Line 4: / Line 4: @@
 |-
 | style="background-color:#F0F0F0; width:15%" |[[File:Ivy_Abraham.JPG|frameless|upright=0.3|center]]
-| style="width:35%" |<big>[[User:Ivyabraham|Ivy Abraham, MD]]<br>University of Illinois at Chicago<br>Chicago, IL</big>
+| style="width:35%" |<big>[[User:Ivyabraham|Ivy Abraham, MD]]<br>University of Chicago Ingalls Memorial Hospital<br>Harvey, IL</big>
 | style="background-color:#F0F0F0; width:15%" |[[File:nkv.jpg|frameless|upright=0.3|center]]
 | style="width:35%" |<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>University of Illinois at Chicago<br>Chicago, IL</big>

Difference between revisions of "Periampullary adenocarcinoma"